ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2807

Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment

Louis Bernard1, Aurélien Dinh2, Idir Ghout3, Valérie Zeller4, Bertrand Issartel5, Nadia Belmatoug6, Michel Dupon7 and Denis Mulleman8, 1University hospital of Tours, Tours, France, 2University hospital of Paris, Garches, France, 3Biostatistic, University Hospital of Paris, Boulogne, France, 4Internal medicine, La Croix Saint Simon Hospital, Paris, France, 5Clinique du Tonkin, Lyon, France, 6University hospital of Paris, Clichy, France, 7infectious disease, University Hospital of Bordeaux, Bordeaux, France, 8CHU Trousseau Tours, Tours, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antibiotics, spondylarthropathy and treatment options

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Infection Related Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

As for most of bone and joint infection, optimal treatment duration for vertebral osteomyelitis (VO) is unknown. In an era of increasing bacterial resistance, we compare the effectiveness of 6 and 12 weeks antibiotic treatment.

Methods:

We carried out anational, open blind, randomized controlled non-inferiority multicentre trial in 2 parallel groups comparing 6 versus 12 weeks of antibiotic treatment duration.

Adult patients with clinical and radiologic diagnosis of VO (MRI or CT) and a reliable microbiological identification (positive and significative blood culture or needle biopsy) were recruited since 2007 to 2011. At one year, after the end of antibiotic therapy, cure was define as the absence of clinical and biological signs related to VO without the need for additional or alternative antibiotic therapy.

Results:

359 patients were randomized, 175 in the group 12 weeks treatment group and 176 in the group 6 weeks; 240 (69%) were male with mean age 61 years old. Eight patients were secondarily excluded. Median duration between first symptoms and diagnosis was 49 (1-80) days; 182 (52%) patients were febrile at diagnosis and 237 (68%) had positive blood culture. Infective endocarditis was present in 70 (20%) cases. Main bacteria involved were Staphylococcus aureus (n=143, 41%), Coagulase negativeStaphylococci (n=52, 15%) and Streptococcus non enterococcus (n=63, 18%).

At baseline, characteristics were similar in both group of treatment duration. During follow up, difference was non significative in both groups regarding median duration of parenteral antibiotictherapy, median length of hospitalization stay, most frequent antibiotics for oral treatment (rifadin and fluoroquinolon). Adverse events occurred in 100 cases of whom 26 deaths. In the intention to treat analysis, cure rates in the 6 weeks treatment group and in the  12 weeks treatment group were respectively 91% (159/171) and 91% (160/176)with a difference non significative between the two groups.

Conclusion:

We have demonstrated in this large multicentre randomized clinical trial that 6 weeks of antibiotic treatment duration is as effective as 12 for VO.

 


Disclosure:

L. Bernard,
None;

A. Dinh,
None;

I. Ghout,
None;

V. Zeller,
None;

B. Issartel,
None;

N. Belmatoug,
None;

M. Dupon,
None;

D. Mulleman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-vertebral-osteomyelitis-a-randomized-clinical-trial-comparing-6-versus-12-weeks-of-antibiotic-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology